These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 26990539)

  • 1. Discovery of a Novel, Orally Efficacious Liver X Receptor (LXR) β Agonist.
    Zheng Y; Zhuang L; Fan KY; Tice CM; Zhao W; Dong C; Lotesta SD; Leftheris K; Lindblom PR; Liu Z; Shimada J; Noto PB; Meng S; Hardy A; Howard L; Krosky P; Guo J; Lipinski K; Kandpal G; Bukhtiyarov Y; Zhao Y; Lala D; Van Orden R; Zhou J; Chen G; Wu Z; McKeever BM; McGeehan GM; Gregg RE; Claremon DA; Singh SB
    J Med Chem; 2016 Apr; 59(7):3264-71. PubMed ID: 26990539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, structure activity relationships and X-Ray co-crystallography of non-steroidal LXR agonists.
    Bennett DJ; Carswell EL; Cooke AJ; Edwards AS; Nimz O
    Curr Med Chem; 2008; 15(2):195-209. PubMed ID: 18220775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quinoline-3-carboxamide containing sulfones as liver X receptor (LXR) agonists with binding selectivity for LXRbeta and low blood-brain penetration.
    Hu B; Bernotas R; Unwalla R; Collini M; Quinet E; Feingold I; Goos-Nilsson A; Wilhelmsson A; Nambi P; Evans M; Wrobel J
    Bioorg Med Chem Lett; 2010 Jan; 20(2):689-93. PubMed ID: 19962892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis of 4-(3-biaryl)quinoline sulfones as potent liver X receptor agonists.
    Ullrich JW; Morris R; Bernotas RC; Travins JM; Jetter J; Unwalla R; Quinet E; Nambi P; Feingold I; Huselton C; Enroth C; Wilhelmsson A; Goos-Nilsson A; Wrobel J
    Bioorg Med Chem Lett; 2010 May; 20(9):2903-7. PubMed ID: 20382019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver X receptor (LXR) partial agonists: biaryl pyrazoles and imidazoles displaying a preference for LXRβ.
    Kick E; Martin R; Xie Y; Flatt B; Schweiger E; Wang TL; Busch B; Nyman M; Gu XH; Yan G; Wagner B; Nanao M; Nguyen L; Stout T; Plonowski A; Schulman I; Ostrowski J; Kirchgessner T; Wexler R; Mohan R
    Bioorg Med Chem Lett; 2015 Jan; 25(2):372-7. PubMed ID: 25435151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of a new binding mode for a series of liver X receptor agonists.
    Kopecky DJ; Jiao XY; Fisher B; McKendry S; Labelle M; Piper DE; Coward P; Shiau AK; Escaron P; Danao J; Chai A; Jaen J; Kayser F
    Bioorg Med Chem Lett; 2012 Apr; 22(7):2407-10. PubMed ID: 22406115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 4-(3-Aryloxyaryl)quinoline sulfones are potent liver X receptor agonists.
    Bernotas RC; Singhaus RR; Kaufman DH; Travins JM; Ullrich JW; Unwalla R; Quinet E; Evans M; Nambi P; Olland A; Kauppi B; Wilhelmsson A; Goos-Nilsson A; Wrobel J
    Bioorg Med Chem Lett; 2010 Jan; 20(1):209-12. PubMed ID: 19932617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 1-(3-Aryloxyaryl)benzimidazole sulfones are liver X receptor agonists.
    Travins JM; Bernotas RC; Kaufman DH; Quinet E; Nambi P; Feingold I; Huselton C; Wilhelmsson A; Goos-Nilsson A; Wrobel J
    Bioorg Med Chem Lett; 2010 Jan; 20(2):526-30. PubMed ID: 20006495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Skeletal muscle as a target of LXR agonist after long-term treatment: focus on lipid homeostasis.
    Archer A; Laurencikiene J; Ahmed O; Steffensen KR; Parini P; Gustafsson JÅ; Korach-André M
    Am J Physiol Endocrinol Metab; 2014 Mar; 306(5):E494-502. PubMed ID: 24368671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 3-(3-Aryloxyaryl)imidazo[1,2-a]pyridine sulfones as liver X receptor agonists.
    Singhaus RR; Bernotas RC; Steffan R; Matelan E; Quinet E; Nambi P; Feingold I; Huselton C; Wilhelmsson A; Goos-Nilsson A; Wrobel J
    Bioorg Med Chem Lett; 2010 Jan; 20(2):521-5. PubMed ID: 20005711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and structure-guided optimization of tert-butyl 6-(phenoxymethyl)-3-(trifluoromethyl)benzoates as liver X receptor agonists.
    Matsui Y; Yamaguchi T; Yamazaki T; Yoshida M; Arai M; Terasaka N; Honzumi S; Wakabayashi K; Hayashi S; Nakai D; Hanzawa H; Tamaki K
    Bioorg Med Chem Lett; 2015 Sep; 25(18):3914-20. PubMed ID: 26238323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. X-ray structures of the LXRalpha LBD in its homodimeric form and implications for heterodimer signaling.
    Fradera X; Vu D; Nimz O; Skene R; Hosfield D; Wynands R; Cooke AJ; Haunsø A; King A; Bennett DJ; McGuire R; Uitdehaag JC
    J Mol Biol; 2010 May; 399(1):120-32. PubMed ID: 20382159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and discovery of 2-oxochromene derivatives as liver X receptor β-selective agonists.
    Matsuda T; Okuda A; Watanabe Y; Miura T; Ozawa H; Tosaka A; Yamazaki K; Yamaguchi Y; Kurobuchi S; Koura M; Shibuya K
    Bioorg Med Chem Lett; 2015 Mar; 25(6):1274-8. PubMed ID: 25677664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous activation of the liver X receptors (LXRα and LXRβ) drives murine collagen-induced arthritis disease pathology.
    Asquith DL; Miller AM; Reilly J; Kerr S; Welsh P; Sattar N; McInnes IB
    Ann Rheum Dis; 2011 Dec; 70(12):2225-8. PubMed ID: 21859686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting selective liver X receptor β agonists using multiple machine learning methods.
    Li Y; Wang L; Liu Z; Li C; Xu J; Gu Q; Xu J
    Mol Biosyst; 2015 May; 11(5):1241-50. PubMed ID: 25734698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and Synthesis of a Novel Series of Liver X Receptor Antagonists.
    Nian S; Gan X; Tan X; Yu Z; Wang P; Chen X; Wang G
    Chem Pharm Bull (Tokyo); 2015; 63(8):628-35. PubMed ID: 26062802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of LXRs using the synthetic agonist GW3965 represses the production of pro-inflammatory cytokines by murine mast cells.
    Nunomura S; Okayama Y; Matsumoto K; Hashimoto N; Endo-Umeda K; Terui T; Makishima M; Ra C
    Allergol Int; 2015 Sep; 64 Suppl():S11-7. PubMed ID: 26344074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Miniaturization of cell-based beta-lactamase-dependent FRET assays to ultra-high throughput formats to identify agonists of human liver X receptors.
    Chin J; Adams AD; Bouffard A; Green A; Lacson RG; Smith T; Fischer PA; Menke JG; Sparrow CP; Mitnaul LJ
    Assay Drug Dev Technol; 2003 Dec; 1(6):777-87. PubMed ID: 15090224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and optimization of a series of liver X receptor antagonists.
    Jiao X; Kopecky DJ; Fisher B; Piper DE; Labelle M; McKendry S; Harrison M; Jones S; Jaen J; Shiau AK; Escaron P; Danao J; Chai A; Coward P; Kayser F
    Bioorg Med Chem Lett; 2012 Sep; 22(18):5966-70. PubMed ID: 22901900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identify liver X receptor β modulator building blocks by developing a fluorescence polarization-based competition assay.
    Zhang Z; Chen H; Chen Z; Ding P; Ju Y; Gu Q; Xu J; Zhou H
    Eur J Med Chem; 2019 Sep; 178():458-467. PubMed ID: 31202993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.